Sun, Linli published the artcileAnalysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid, HPLC of Formula: 21829-25-4, the publication is Annals of Pharmacotherapy (2022), 56(2), 205-212, database is CAplus and MEDLINE.
Objective: To analyze and discuss the clin. characteristics of dipeptidyl peptidase-4 inhibitor (DPP4i)-induced bullous pemphigoid (BP). Data Sources: We collected case reports of DPP4i-induced BP by searching databases from 2006 to mid-May 2021, as a retrospective anal. Study Selection and Data Extraction: Relevant case reports and case analyses of DPP4i-induced BP were included. Data Synthesis: The median time of symptom onset was 9 mo (range 0.5-59 mo). BP most often occurred in patients receiving vildagliptin (52.63%) followed by linagliptin (27.19%) and sitagliptin (17.54%). Tense bullae and blisters (85.51%) and erythema (82.61%) on the extremities and trunk were the most common presenting symptoms. In total, 64.06% of BP patients were anti-BP180 autoantibody pos., 58.97% were BP180NC16a autoantibody pos., and 31.25% were anti-BP230 autoantibody pos. Skin biopsy revealed subepidermal bulla eosinophil infiltration in 93.85% of BP patients, lymphocyte infiltration in 56.93%, and neutrophil infiltration in 44.62%. Direct immunofluorescence was pos. in 98.94% of BP patients with linear deposition of IgG (97.80%) and/or complement C3 (98.94%) along the basement membrane zone. Indirect immunofluorescence was pos. in 87.88% of BP patients. Complete remission of BP was achieved in 83.64% of patients on DPP4i withdrawal and after 4 mo (range 0.13-72 mo) of follow-up. Relevance to Patient Care and Clin. Practice: This review analyzes and discusses the clin. characteristics of DPP4i-induced BP and provides a reference for the safe and reasonable clin. application of DPP4i. DPP4i drugs are related to the occurrence of BP in diabetic patients, especially elderly men taking vildagliptin.
Annals of Pharmacotherapy published new progress about 21829-25-4. 21829-25-4 belongs to pyridine-derivatives, auxiliary class Membrane Transporter/Ion Channel,Calcium Channel, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C7H5Br2F, HPLC of Formula: 21829-25-4.
Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem